Key Details
The report, Strategic Roadmap for Making Ayurveda Global, presents a phased strategy to transform Ayurveda into a globally recognised, evidence-based healthcare system by 2047. Organised around the pillars of Availability, Acceptability and Propagation, it proposes coordinated reforms across research, regulation, education, manufacturing, healthcare delivery and international partnerships.
Strategic Pillars of the Roadmap
Strategic Pillar | Principal Focus | Key Reforms |
|---|---|---|
Availability | Expand the global Ayurveda ecosystem | Strengthen education, practitioner capacity, research infrastructure, manufacturing, exports and international workforce development. |
Acceptability | Build scientific and regulatory legitimacy | Expand multicountry clinical trials, pharmacovigilance, real-world evidence, WHO-GMP manufacturing, internationally compatible coding systems, insurance acceptance and harmonised quality standards. |
Propagation | Expand international adoption | Strengthen health diplomacy, Medical Value Travel, global branding, international partnerships and multilateral engagement. |
Mission Roadmap to 2047
Timeline | Strategic Priorities |
|---|---|
Up to 2029 | Strengthen scientific research, quality assurance, WHO-GMP adoption, practitioner registry, exports, Ayush Visa reforms, Medical Value Travel and global branding. |
Up to 2035 | Establish International Ayurveda Centres of Excellence, expand global education and research networks, strengthen regulatory recognition and publish annual Global Ayurveda Evidence Reports. |
Up to 2047 | Integrate Ayurveda into multiple national healthcare systems, expand international insurance coverage, strengthen global research and clinical networks, and establish Ayurveda as a globally recognised evidence-based healthcare system. |
Summary
Globalising Ayurveda Requires Scientific Legitimacy
The report argues that Ayurveda’s international expansion will depend less on cultural promotion than on scientific legitimacy built through robust evidence, regulatory alignment and quality assurance. Although global interest in traditional medicine is growing, wider adoption remains constrained by limited clinical evidence, fragmented regulations, inconsistent standards and weak integration with mainstream healthcare.
The roadmap therefore shifts the policy focus from promoting Ayurveda internationally to building the scientific and regulatory foundations needed for global acceptance. It prioritises multicountry clinical trials, pharmacovigilance, real-world evidence, internationally compatible coding frameworks and harmonised quality standards to support Ayurveda’s integration into healthcare delivery, insurance systems and health information infrastructure.
The report distinguishes global visibility from global legitimacy, arguing that long-term adoption will depend on demonstrating safety, efficacy and quality through internationally recognised evidence and regulatory standards.
A Whole-of-Ecosystem Strategy
Rather than treating research, education, manufacturing, healthcare delivery and exports as separate policy domains, the roadmap brings them together within a strategy organised around Availability, Acceptability and Propagation. It recommends WHO-GMP manufacturing, an export-oriented Ayurvedic Pharmacopoeia, expanded NABH accreditation, International Ayurveda Centres of Excellence, globally aligned education and practitioner mobility, alongside stronger international research partnerships to build a globally competitive Ayurveda ecosystem.
Health Diplomacy Supports Global Integration
The roadmap positions health diplomacy and Medical Value Travel (MVT) as strategic instruments for expanding Ayurveda’s international presence. It proposes leveraging the WHO Global Traditional Medicine Centre, Indian missions abroad and multilateral platforms to strengthen scientific collaboration, regulatory cooperation and international recognition.
Supporting measures include reforms to the Ayush Visa, expansion of internationally accredited treatment centres, dedicated Ayurveda Medical Value Travel hubs, wider use of teleconsultation and improved insurance portabilityfor international patients.
Mission-Based Governance Will Determine Success
The report concludes that globalising Ayurveda will require mission-based implementation rather than isolated policy initiatives. It proposes clearly defined roles for government, regulators, research institutions, academia, healthcare providers and industry, supported by dedicated coordination mechanisms and milestones for 2029, 2035 and 2047.
It also emphasises that digital and regulatory interoperability - including internationally compatible coding systems, harmonised quality standards and interoperable health information systems - will be essential for integrating Ayurveda into healthcare delivery and clinical practice worldwide. Rather than a branding exercise, the roadmap presents globalisation as a long-term process of building scientific credibility, regulatory acceptance and institutional partnerships.
What Is Medical Value Travel?
Medical Value Travel (MVT) refers to cross-border travel undertaken to receive healthcare services. Unlike conventional medical tourism, MVT emphasises the quality, safety, affordability and continuity of medical care rather than travel alone. The roadmap identifies Ayurveda-based Medical Value Travel as an important avenue for expanding India’s healthcare exports through internationally accredited treatment centres, improved visa policies, insurance portability, teleconsultation and globally recognised quality standards. It argues that sustained growth in MVT will depend on integrating Ayurveda into internationally trusted healthcare systems rather than promoting it solely as a wellness experience.
Policy Relevance
Global acceptance of traditional medicine increasingly depends on scientific legitimacy rather than cultural recognition alone. Countries seeking to internationalise traditional healthcare systems will need sustained investment in clinical research, quality assurance, pharmacovigilance and regulatory harmonisation alongside international promotion.
Healthcare exports are becoming increasingly linked to regulatory and institutional capacity.Manufacturing standards, practitioner accreditation, internationally recognised evidence and compatible regulatory frameworks will increasingly determine access to overseas healthcare markets and insurance systems.
Medical Value Travel is evolving from a tourism initiative into a healthcare strategy. Expanding accredited treatment centres, insurance portability, teleconsultation and internationally recognised clinical standards can strengthen India’s position as a destination for specialised healthcare services while improving patient confidence.
Health diplomacy is becoming an important instrument for expanding healthcare partnerships.Collaboration through multilateral institutions, bilateral agreements and international research networks can strengthen scientific exchange, regulatory cooperation and wider acceptance of Ayurveda across national health systems.
Mission-based implementation will require sustained coordination across government, regulators, academia and industry. Achieving the roadmap’s milestones for 2029, 2035 and 2047 will depend on aligning research, education, manufacturing, exports and healthcare delivery through clearly defined institutional responsibilities and long-term monitoring.
For India, the roadmap positions Ayurveda within a broader strategy linking healthcare, research, exports, innovation and international engagement. Long-term success will depend on building globally trusted institutions that support evidence generation, regulatory credibility and high-quality healthcare delivery rather than relying primarily on cultural promotion or branding.
Follow the Full Report Here: Strategic Roadmap for Making Ayurveda Global